Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy
Launched by UNIVERSITÄT DUISBURG-ESSEN · Nov 27, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effects of a specific type of acupuncture called hypoglossal acupuncture to help improve taste issues (known as dysgeusia) in cancer patients who are undergoing chemotherapy. The trial compares this acupuncture treatment to a fake version (sham acupuncture) and standard dietary recommendations to see which method works best for alleviating the unpleasant taste changes some patients experience during their treatment.
To participate in this study, individuals should be between the ages of 65 and 74, currently undergoing chemotherapy with certain drugs, and experiencing significant taste changes. They must also be willing to sign a consent form to join the trial. Participants can expect to receive either the hypoglossal acupuncture, the sham treatment, or dietary advice over the course of the study, and their taste experiences will be carefully monitored. This trial is currently looking for eligible participants, and it aims to find new ways to improve quality of life for those dealing with taste problems during cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Initial treatment with platinum-containing or taxane-based CTX (regardless of the the length of the CTX cycle)
- • Senological, gynecological or internistic tumors
- • Phantogeusia (on average ≥4 NRS)
- • Willingness to participate in the study and written informed consent
- Exclusion Criteria:
- • Severe stomatitis
- • Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of drugs with taste disorders as side effects
- • Leucopenia/neutropenia
- • Intake of anticoagulants
- • Smoking
- • Severe physical or mental comorbidity (due to which the patient is unable to participate in the study)
- • Participation in other CAM treatments within the integrative oncology care
- • Participation in other studies on the effectiveness of interventions for oral complications
About Universität Duisburg Essen
The Universität Duisburg-Essen is a prominent academic institution in Germany, renowned for its commitment to research and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its interdisciplinary expertise and state-of-the-art facilities to advance clinical research initiatives. With a focus on improving patient outcomes, the university actively collaborates with healthcare professionals, industry partners, and regulatory bodies to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to enhancing clinical knowledge and fostering new therapeutic approaches, Universität Duisburg-Essen plays a pivotal role in the evolution of modern healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, Nrw, Germany
Mannheim, , Germany
Stuttgart, , Germany
Patients applied
Trial Officials
Gustav Dobos, Prof., MD
Study Director
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials